Answer
Lebrikizumab injection-site reactions include pain and erythema, reported in 2.6% of patients versus 1.5% with placebo; 95% were mild or moderate, and fewer than 0.5% of patients discontinued treatment.
Sources for this answer
- Ebglyss 250 mg solution for injection in pre-filled syringeAlmirall Limited · emc · SmPC §4.8 Undesirable effects · Version 5Document updated
Sources checked